Next Article in Journal
Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities
Previous Article in Journal
In Vivo Evaluation of Miconazole-Nitrate-Loaded Transethosomal Gel Using a Rat Model Infected with Candida albicans
Previous Article in Special Issue
Design, Synthesis and Biological Assessment of N′-(2-Oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazides as Potential Anti-Proliferative Agents toward MCF-7 Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 5
10.3390/ph17050548
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

NMI-SO2Cl2-Mediated Amide Bond Formation: Facile Synthesis of Some Dihydrotriazolopyrimidine Amide Derivatives as Potential Anti-Inflammatory and Anti-Tubercular Agents

by
Aravinda Babu
1,
Kenchaiah Sunil
1,
Ayyiliath Meleveetil Sajith
1,
Eeda Koti Reddy
2,
Sougata Santra
3,
Grigory V. Zyryanov
3,4,
Talavara Venkatesh
5,
Somashekara Bhadrachari
6 and
Muthipeedika Nibin Joy
3,*
1
Department of Chemistry, SSIT, Sri Siddhartha Academy of Higher Education, Tumkur 572107, Karnataka, India
2
Department of Chemistry, Vignan’s Foundation for Science, Technology and Research—VFSTR (Deemed to be University), Vadlamudi, Guntur 522213, Andhra Pradesh, India
3
Laboratory of Organic Synthesis, Institute of Chemical Technology, Ural Federal University, 19 Mira Street, Yekaterinburg 620002, Russia
4
I. Ya. Postovskiy Institute of Organic Synthesis, Ural Division of the Russian Academy of Sciences, 22 S. Kovalevskoy Street, Yekaterinburg 620219, Russia
5
Department of P.G Studies and Research in Chemistry, Kuvempu University, Jnana Sahyadri, Shankaraghatta, Shimoga 577451, Karnataka, India
6
Department of Chemistry, Smt. Indira Gandhi Government First Grade Women’s College, Sagar 577401, Karnataka, India
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(5), 548; https://doi.org/10.3390/ph17050548
Submission received: 21 November 2023 / Revised: 17 April 2024 / Accepted: 20 April 2024 / Published: 24 April 2024
(This article belongs to the Special Issue Design, Synthesis, and Biological Evaluation of Heterocyclic Compounds)
Browse Figures
Versions Notes

Abstract

:
Facile access to some novel biologically relevant dihydrotriazolopyrimidine carboxylic acid-derived amide analogues using NMI/SO2Cl2, and aromatic and aliphatic primary and secondary amines, is reported herein. The role of N-methylimidazole (NMI) as the base and sulfuryl chloride (SO2Cl2) as the coupling reagent has been effectively realized in accessing these molecules in good to excellent yields. The feasibility of the developed protocol has also been extended to the gram-scale synthesis of N-benzylbenzamide in a 75% yield from benzoic acid and benzyl amine. The newly synthesized compounds were tested via in vitro anti-inflammatory and anti-tubercular activity studies. The compounds 6aa and 6be were found to be the most active anti-inflammatory agents, whereas 6cb and 6ch were found to exhibit promising anti-tubercular potency when compared to other synthesized molecules. The structure–activity relationship (SAR) studies revealed the importance of the presence of electron-donating functionalities in enhancing the anti-inflammatory potential of the newly synthesized molecules. However, the presence of electron-withdrawing substituents was found to be significant for improving their anti-tubercular potency.

1. Introduction

Nitrogen-containing heterocyclic moieties play a significant role nowadays, as underlined by their presence in various pharmacologically active molecules [1,2,3]. Among the various nitrogen-containing compounds discovered so far, the heterocyclic moieties based on triazoles and dihydropyrimidines are of profound importance [4,5]. They are reported to possess various pharmacological activities, such as antimicrobial, anti-inflammatory, anticancer, antimalarial and antioxidant properties [6,7,8,9,10]. In addition to this, triazolopyrimidine derivatives exhibit acetylcholinesterase (AChE) inhibitory properties, an important factor necessary for the treatment of Alzheimer’s disease (AD) [1,2,3,11,12,13]. Among the various triazole derivatives reported hitherto, the compounds containing 1,2,4-triazole have significant applications in medicinal chemistry [14,15,16]. Hence, the synthesis of novel heterocyclic compounds containing 1,2,4-triazoles and dihydropyrimidines is highly significant in medicinal chemistry.
Inflammation is a defensive immune reaction that develops in our body against mechanical injury, pathogens or irritants. The healing process occurring in the body is initiated by inflammation after subjecting it to various physiological adaptations to minimize the tissue damage [17,18,19]. On the other hand, long-term inflammatory conditions are not very useful for the body and can lead to various disorders, like multiple sclerosis, atherosclerosis, retinitis, psoriasis, inflammatory bowel diseases, osteoarthritis and rheumatoid arthritis. Some of these inflammatory diseases can even lead to death [20,21], and hence, there is a continuous need to discover new anti-inflammatory agents from time to time. Tuberculosis (TB) is an illness caused by Mycobacterium tuberculosis and is considered a serious life-threatening disease worldwide [22]. TB has resulted in over 1.6 million deaths and 10.6 million clinical cases (until 2021) according to a recent report of the World Health Organization (WHO) [23]. Considering these observations, development of novel anti-TB agents has been the aim of many researchers around the globe. Nevertheless, it has been reported that only a few compounds have reached the clinical trials stage so far, which indicates a vital need to develop new anti-TB agents with excellent mechanisms of action, low toxicity, improved potency and short therapy duration profiles [24].
In the modern arena of drug discovery, amide and thioamide functional groups are reported to act as efficient linkers [25]. When attached to diverse heterocyclic moieties, the amides are rationalized to act as good linkers by promoting suitable binding to the active site of the protein and thereby improving its pharmacological activities [26]. Considering the biological importance of 1,2,4-triazoles, dihydropyrimidines and amides, the development of an efficient amide formation methodology to access these otherwise challenging amides is of immense potential. In view of these aforementioned observations and as a continuation of our research in developing biologically active substances [27,28,29], we were interested in synthesizing some novel dihydrotriazolopyrimidine derivatives containing amide functionality. Accordingly, we herein report the synthesis of a series of dihydrotriazolopyrimidine derivatives linked to amides by utilizing the N-methylimidazole (NMI) and sulfuryl chloride (SO2Cl2)-mediated amide bond formation reaction. The results of the preliminary in vitro screening of these synthesized compounds as potential anti-inflammatory and anti-tubercular agents are also reported.

2. Results and Discussion

2.1. Chemistry

Initially, we started our synthetic route by synthesizing the key acid intermediates 4a–c, as summarized in Scheme 1. The one-pot, three-component reaction of different benzaldehydes 1a–c, pyruvic acid 2 and 4H-1,2,4-triazol-3-amine 3 in acetic acid afforded the acid intermediates 4a–c in good to excellent yields. The key intermediates 4a–c were then treated with different amines 5 in view of synthesizing an array of dihydrotriazolopyrimidine derivatives containing amide functionality.
As a model reaction for the optimization studies, we treated the acid intermediate 4a with 4-methoxybenzylamine 5a (Table 1). A variety of coupling reagents and bases were screened in different solvents for the reaction optimization. Gratifyingly, we obtained the expected product 6aa in a 92% isolated yield when the reaction was carried out at room temperature by employing NMI as the base and SO2Cl2 as the coupling reagent in dichloromethane (DCM) solvent (Table 1, entry 2). The usage of other reagent combinations resulted in lesser yields of the desired product (Table 1, entries 5–9). Nevertheless, the desired product was obtained in a satisfactory yield when trifluoromethanesulfonyl chloride (TfCl) and methanesulfonyl chloride (MsCl) were employed as the coupling reagent instead of SO2Cl2 (Table 1, entries 10,11). DCM was found to be the most suitable solvent when compared to DMF and THF (Table 1, entries 12,13).
After the detailed reaction optimization studies, we shifted our attention to evaluating the substrate scope of the developed methodology. Keeping this in mind, we treated the acid intermediates 4a–c with different amines 5a–i (Scheme 2). Gratifyingly, the amines reacted well to furnish the respective amides 6 in reasonable yields. The amines 5a, 5g and 5h afforded the expected amides in excellent yields (up to a 92% isolated yield), whereas the other amines furnished the desired products in good to satisfactory yields (75–88% isolated yield).
To further expand the usefulness of the developed synthetic methodology, the protocol was further employed for scalability studies (Scheme 3). Accordingly, the gram-scale synthesis of 6de was successfully executed using this methodology by employing benzoic acid 4d and benzyl amine 5e as the reactants. The method provides an alternative atom economic and cheaper protocol for accessing diverse amides. The method avoids the use of coupling agents, which need further processing to remove the side products associated with these reagents. The desired amide product 6de was obtained in a 75% isolated yield when the reaction was carried out for 5 h.
The possible mechanism for the three-component reaction resulting in the formation of the key acid intermediates 4a–c has been illustrated in Scheme 4 [30]. Initially, aldehydes 1a–c and pyruvic acid 2 undergo the aldol condensation reaction to generate intermediate I. This intermediate undergoes the imine formation reaction with 4H-1,2,4-triazol-3-amine 3 in the presence of acetic acid to generate intermediate II. This intermediate undergoes cyclization followed by a 1,3-hydrogen shift between the nitrogen atoms to form the key acid intermediates 4a–c.
The plausible mechanism for the formation of the different amides has been proposed in Scheme 5 by taking acid 4a as an example [28]. During our initial optimization studies (Table 1, entry 7), we obtained the expected product in a lesser yield when NMI was replaced by triethylamine (TEA) as the base. This observation eliminated the possibility of the formation of acid chloride (by the reaction of carboxylic acid and SO2Cl2) as the first step in the reaction mechanism. Hence, it is speculated that the first step involves the generation of intermediate complex III by the reaction of N-methylimidazole and sulfuryl chloride. Subsequently, the carboxylic acid group from 4a reacts with this complex and generates a highly activated chlorosulfonic anhydride intermediate IV. Finally, the nucleophilic attack of amines 5a–i takes place on this intermediate, leading to the formation of the corresponding amides 6.

2.2. Biological Activity of Synthesized Compounds

2.2.1. Anti-Inflammatory Activity

All the newly synthesized dihydrotriazolopyrimidine amide derivatives 6aa–6ci were screened for in vitro anti-inflammatory potential. The studies were performed by anti-denaturation assay and diclofenac sodium was utilized as the reference standard for the anti-inflammatory activity evaluation [31]. The compounds 6aa–6ci and the standard were prepared in different concentrations (100, 200, 400, 800 and 1600 μg/mL) and the determination of anti-inflammatory activity was subsequently performed (Table 2).
Amongst the tested compounds, 6aa and 6be displayed superior anti-inflammatory activity (40 and 44% inhibition of denaturation at a 100 μg/mL concentration) when compared to the standard drug, diclofenac. The compound 6be exhibited 44% inhibition of denaturation at a 100 μg/mL concentration, while diclofenac sodium displayed 41% inhibition at this concentration. However, the compound 6aa showed 40% inhibition at a 100 μg/mL concentration. These two compounds also possessed a comparable percentage of inhibition at all the concentrations tested. Moreover, the compounds 6ac, 6bc and 6bg also showed promising anti-inflammatory activity when compared to the reference standard. These compounds demonstrated a superior percentage of inhibition when compared with other tested compounds from the same series. In contrast, the compounds 6ab, 6ai, 6cb, 6cc, 6ce, 6cf, 6ch and 6ci showed the lowest percentage of inhibition of denaturation at all the concentrations tested. All the other tested compounds displayed moderate anti-inflammatory potential. Therefore, the compound 6be was identified to be the most promising one among the tested compounds, as it displayed a slightly superior activity profile when compared to that of the standard drug, diclofenac sodium.

2.2.2. Anti-Tubercular Activity Studies

The in vitro anti-tubercular activity evaluation of the synthesized compounds 6aa–6ci was carried out against various TB strains, as summarized in Table 3. The studies were carried out in two stages by the resazurin assay method by employing rifampicin and isoniazid as the reference standards [32]. Initially, the anti-tubercular activity evaluations were performed at 1, 10 and 100 μg/mL concentrations against different TB strains—namely Mycobacterium tuberculosis H37Rv, Mycobacterium smegmatis (ATCC 19420) and Mycobacterium fortuitum (ATCC 19542)—and the minimum inhibitory concentration (MIC) values were examined (Table 3). In the next stage, the more active compounds from the preliminary tests were subjected to a second level of screening at lower concentrations. The activity of the tested compounds against the MDR-TB strain was also evaluated during this phase, along with the three previously screened TB strains. The compounds that were active at 10 μg/mL concentrations or lower were used for this second stage of screening and the molecules that were active at 100 μg/mL or more were discarded. All the compounds selected for the second level of screening were evaluated at 0.3125, 0.625, 1.25, 2.5 and 5.0 μg/mL concentrations.
Among the newly synthesized compounds 6aa–6ci, the anti-tubercular activity potential of some of the molecules was found to be promising, as they displayed MIC values in the range of 1 and 10 μg/mL concentrations against Mycobacterium tuberculosis H37Rv strain (Table 3). The compounds 6cb and 6ch were found to be potent at 0.625 μg/mL concentrations against the Mycobacterium tuberculosis H37Rv strain, whereas the compounds 6ab, 6cc, 6cf and 6cg were active at 1.25 μg/mL concentrations. Moreover, the compounds 6cb–6ci demonstrated promising anti-tubercular activity against Mycobacterium smegmatis (ATCC 19420) at a concentration of 1.25 μg/mL. It is worth mentioning that most of the tested compounds were not very active against Mycobacterium fortuitum (ATCC 19542) when compared with the reference drug, rifampicin. Furthermore, the compounds 6cb and 6ch showed promising potency against the MDR-TB strain at 6.25 μg/mL. The other tested compounds in this series exhibited lower or modest activity profiles against the various TB strains.

2.2.3. SAR Studies

After evaluating the anti-inflammatory and anti-tubercular properties of the newly synthesized dihydrotriazolopyrimidine amide derivatives 6aa–6ci, SAR studies were carried out to determine the correlation between their promising activity profile and structural specificity (Scheme 6). In this work, we have synthesized 21 dihydrotriazolopyrimidine compounds linked to amide functionality. Our initial efforts were focused on synthesizing various types of amides (Region 1, Scheme 6) and Region 2 was restricted to three different functional groups. The compounds containing varied electronic and steric features were comprised in our anti-inflammatory and anti-tubercular activity studies. The SAR studies paved the way for realizing the importance of some specific electronic features in enhancing the overall pharmacological profile of the tested compounds.
Among the various compounds screened for the anti-inflammatory studies, 6aa and 6be were found to be the most active ones. The enhanced anti-inflammatory potential of 6aa and 6be when compared to the other tested molecules can possibly be due to the presence of electron-donating methoxy groups in these compounds. Alternatively, the compounds containing electron-withdrawing groups were not found to be active as anti-inflammatory agents. Among the compounds screened for anti-tubercular activity studies, 6cb and 6ch were found to be the most active ones. Moreover, the compounds 6ab, 6cc, 6ce, 6cf, 6cg and 6ci were also found to be active as anti-tubercular agents. In these molecules, electron-withdrawing functionalities such as F, Br or Cl are present and this could possibly be the main reason for the higher potency of these compounds. Generally, the presence of electron-withdrawing groups at the phenyl ring increases the lipophilicity of the compound, as evident from the calculated LogP and CLogP (Table 4). Presumably, this will increase their cell permeability and hence improve the overall activity of these compounds [33].
In summary, the presence of electron-donating functionalities at Regions 1 and 2 was found to be necessary for improved anti-inflammatory potential, whereas the existence of electron-withdrawing substituents (at Regions 1 and 2) significantly enhanced the anti-tubercular potential of the synthesized compounds.

3. Materials and Methods

3.1. General Considerations

All the chemicals were purchased from commercial suppliers and used as delivered. The 1H NMR and 13C NMR spectra were recorded at 400 and 100 MHz, respectively (the NMR spectra of all the new compounds are available in the Supplementary Materials). The chemical shifts were reported in parts per million (ppm) and the coupling constants in Hertz (Hz). Tetramethylsilane (TMS) (δ = 0.00 ppm) or the residual solvent peak in DMSO-d6 (δ = 2.50 ppm) and CDCl3 (δ = 7.26 ppm) served as the internal standard for recording [34]. The molecular weights of unknown compounds were checked by the LC-MS 6200 series supplied by Agilent Technology. The microanalyses were performed on a PerkinElmer Series II CHNS/O 2400 elemental analyzer. The melting points were determined using a Stuart SMP 3 apparatus. Thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 TLC plates.

3.2. Experimental Section

3.2.1. General Procedure for the Synthesis of Acid Intermediates 4a–c

A solution of benzaldehydes (1a–c) (5 mmol, 1.0 equiv.), pyruvic acid (2) (5 mmol, 1.0 equiv.) and 4H-1,2,4-triazol-3-amine (3) (5 mmol, 1.0 equiv.) was taken in acetic acid (10 vol) and heated at 90 °C for 1h. After the specified time, the reaction mixture was cooled to room temperature and then water (100 mL) was added to obtain a precipitate. The precipitate was filtered, again washed with water (100 mL) and the solid was dried to obtain the desired acids with different yields.
7-Phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxylic acid (4a)
Yield = 82%; off-white solid. Mp 175–177 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H, COOH), 7.62 (s, 1H, ArH), 7.34 (m, 3H, ArH), 6.26 (d, J = 4.0 Hz, 1H, NH), 5.79 (d, J = 4.0 Hz, 1H, CH). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 150.3, 149.4, 141.3, 129.2, 128.6, 128.1, 127.1, 106.6, 59.7. LC-MS: 243.2 (M+H). Anal. Calculated for C18H16F2N4: C, 59.50; H, 4.16; N, 23.13; found: C, 59.32; H, 4.50; N, 23.11%.
7-(4-Methoxyphenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxylic acid (4b)
Yield = 85%; off-white solid. Mp 171–174 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.9 (s, 1H, COOH), 7.6 (s, 1H, ArH), 7.14 (d, J = 8.3 Hz, 2H, ArH), 6.91 (d, J = 8.3 Hz, 2H, ArH), 6.19 (d, J = 4.0 Hz, 1H, NH), 5.76 (d, J = 4.0 Hz, 1H, CH), 3.73 (s, 3H, OCH3). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 159.6, 150.2, 149.1, 133.4, 128.6, 127.9, 114.5, 106.7, 59.2, 55.6. LC-MS: 273.1 (M+H). Anal. Calculated for C18H16F2N4: C, 57.35; H, 4.44; N, 20.58; found: C, 57.24; H, 4.05; N, 20.54%.
7-(5-Bromo-2-fluorophenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxylic acid (4c)
Yield = 74%; pale yellow solid. Mp 210–215 °C. 1H NMR (400 MHz, DMSO-d6): δ 13.61 (s, 1H, COOH), 10.09 (s, 1H, ArH), 7.77–7.63 (m, 2H, ArH), 7.18 (qd, J = 8.2, 4.2 Hz, 1H, ArH), 6.79 (dd, J = 9.2, 3.1 Hz, 1H, ArH), 6.53 (d, J = 3.8 Hz, 1H, NH), 5.7 (d, J = 3.7 Hz, 1H, CH). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 163.1, 160.8, 150.8, 149.9, 141.3 (d, J = 6.4 Hz), 135.6 (d, J = 8.1 Hz), 129.3, 117.9 (d, J = 22.4 Hz), 116.7 (d, J = 23.7 Hz), 115.8 (d, J = 3.0 Hz), 102.4 (d, J = 179.8 Hz). LC-MS: 340.1 (M+2H). Anal. Calculated for C18H16F2N4: C, 42.50; H, 2.38; N, 16.52; found: C, 42.52; H, 2.17; N, 16.45%.

3.2.2. General Procedure for the Synthesis of the Final Compounds

Sulfuryl chloride (2 mmol, 2.0 equiv.) was added to a solution of N-methyl imidazole (2 mmol, 2.0 equiv.) in dichloromethane (10 vol) and stirred for 15 min. To that mixture, acids (4a–c) (1 mmol, 1.0 equiv.) were added, followed by amines (5a–f) (1.2 mmol, 1.2 equiv.). The reaction mixture was stirred for 2 h at room temperature and then quenched with water (10 vol). The organic layer was washed with saturated sodium bicarbonate solution (10 mL) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under a vacuum. The residue obtained was washed with dichloromethane to obtain the respective amides in varying yields.
N-(4-Methoxybenzyl)-7-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6aa)
Yield = 92%; off-white solid. Mp 151–154 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.7 (s, 1H, NHCH2), 8.85 (t, J = 6.2 Hz, 1H, ArH), 7.62 (s, 1H, ArH), 7.33 (dq, J = 14.6, 7.5 Hz, 3H, ArH), 7.21 (d, J = 7.9 Hz, 4H, ArH), 6.87 (d, J = 8.1 Hz, 2H, ArH), 6.23 (d, J = 3.9 Hz, 1H, NH), 5.6 (d, J = 4.0 Hz, 1H, CH), 4.3 (t, J = 4.8 Hz, 2H, CH2), 3.71 (s, 3H, OCH3). 13C NMR (100 MHz, DMSO-d6): δ 161.6, 158.8, 150.3, 149.4, 141.7, 131.3, 130.2, 129.3, 129.1, 128.6, 127.3, 114.1, 101.7, 59.6, 55.5, 42.6. LC-MS: 362.1 (M+H). Anal. Calculated for C18H16F2N4: C, 66.47; H, 5.30; N, 19.38; found: C, 66.36; H, 5.24; N, 19.25%.
N-(4-Fluorobenzyl)-7-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ab)
Yield = 86%; off-white solid. Mp 152–155 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.87 (s, 1H, NHCH2), 8.95 (t, J = 6.0 Hz, 1H, ArH), 7.69 (m, 2H, ArH), 7.32 (dd, J = 8.4, 5.6 Hz 2H, ArH), 7.16 (m, 5H, ArH), 6.79 (d, J = 3.8 Hz, 1H, ArH), 6.52 (s, 1H, NH), 5.61 (d, J = 4.1 Hz, 1H, CH), 4.41 (t, J = 5.6 Hz, 2H, CH2). 13C NMR (100 MHz, DMSO-d6): δ 162.4, 150.2, 149.1, 133.7, 130.5, 129.4, 128.7, 115.5, 114.5, 101.9, 59, 55.6, 42.4. LC-MS: 350.1 (M+H). Anal. Calculated for C18H16F2N4: C, 65.32; H, 4.62; N, 20.05; found: C, 65.05; H, 4.25; N, 19.93%.
7-Phenyl-N-(1-phenylethyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ac)
Yield = 86%; off-white solid. Mp 151–154 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.65 (s, 1H, NHCH2), 8.72 (t, J = 7.4 Hz, 1H, ArH), 7.62 (d, J = 1.7 Hz, 1H, ArH), 7.36 (m, J = 6H, ArH), 7.27–7.17 (m, 3H, ArH), 6.25 (d, J = 3.8 Hz, 1H, NH), 5.78 (d, J = 4.3 Hz, 1H, CH), 5.05 (p, J = 7.1 Hz, 1H, CH), 1.49–1.33 (m, 3H, CH3). 13C NMR (100 MHz, DMSO-d6): δ 160.9, 150.3, 149.4, 144.6, 141.7, 130.1, 129.2, 128.7, 128.6, 127.3, 127.2, 126.5, 102.1, 59.7, 49.1, 22.4. LC-MS: 345.1 (M+H). Anal. Calculated for C18H16F2N4: C, 69.55; H, 5.54; N, 20.28; found: C, 69.55; H, 5.54; N, 20.49%.
N-Methyl-7-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ad)
Yield = 80%; off-white solid. Mp 145–148 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.7 (s, 1H, NHCH2), 8.35 (q, J = 4.5 Hz, 1H, ArH), 7.62 (d, J = 2.4 Hz, 1H, ArH), 7.37 (dd, J = 8.1, 6.5 Hz, 3H, ArH), 7.24–7.2 (m, 2H, ArH), 6.23 (d, J = 3.9 Hz, 1H, NH), 5.6 (d, J = 4.0 Hz, 1H, CH), 2.69 (d, J = 4.5 Hz, 3H, CH3). 13C NMR (100 MHz, DMSO-d6): δ 162.8, 161.9, 160.5, 159.6, 150.1, 149.1, 135.6, 133.7, 130.1, 129.9, 129.8, 128.7, 115.6, 114.5, 101.9, 59.1, 42.4. LC-MS: 256.1 (M+H). Anal. Calculated for C18H16F2N4: C, 61.17; H, 5.13; N, 27.43; found: C, 61.43; H, 5.40; N, 27.79%.
7-Phenyl-N-(prop-2-yn-1-yl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6af)
Yield = 82%; off-white solid. Mp 140–141 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H, NHCH2), 8.84 (t, J = 5.6 Hz, 1H, ArH), 7.57 (s, 1H, ArH), 7.14 (d, J = 8.3 Hz, 2H, ArH), 6.9 (d, J = 8.3 Hz, 2H, ArH), 6.16 (d, J = 3.8 Hz, 1H, NH), 5.63 (d, J = 4.3 Hz, 1H, CH), 3.94 (dd, J = 5.67, 2.5 Hz, 2H, CH2), 3.11 (t, J = 2.5 Hz, 1H, CH). 13C NMR (100 MHz, DMSO-d6): δ 160.9, 150.3, 149.3, 144.8, 141.7, 130.1, 128.6, 127.3, 101.1, 59.7, 49.1, 22.4. LC-MS: 280.1 (M+H). Anal. Calculated for C15H13N5O5: C, 64.51; H, 4.69; N, 25.07; found: C, 64.61; H, 4.35; N, 25.04%.
N-Ethyl-N,7-diphenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ag)
Yield = 77%; off-white solid. Mp 168–174 °C. 1H NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H, NH), 7.50–7.37 (m, 6H, ArH), 7.35–7.29 (m, 4H, ArH), 6.25 (d, J = 3.5 Hz, 1H, ArH), 4.61 (d, J = 3.5 Hz, 1H), 3.93 (m, 1H, CH), 3.64 (m, 1H, CH), 1.08 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, DMSO-d6): δ 163.8, 150.7, 149.3, 142.2, 135.1, 132.4, 129.5, 127.6, 117.7, 98.1, 58.9, 44.4, 12.9. LC-MS: 346.1 (M+H). Anal. Calculated for C20H19N5O: C, 69.55; H, 5.54; N, 20.28; found: C, 69.33; H, 5.34; N, 19.93%.
N-Cyclohexyl-7-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ai)
Yield = 85%; off-white solid. Mp 161–164 °C. 1H NMR (400 MHz, DMSO-d6): δ 10.15 (s, 1H, NH), 8.21 (d, J = 7.8 Hz, 1H, ArH), 7.29–719 (m, 5H, ArH), 6.55 (d, J = 3.6 Hz, 1H, ArH), 5.74 (d, J = 3.7 Hz, 1H, CH), 3.66 (m, 1H, CH), 1.84–1.65 (m, 4H, CH2), 1.58 (dd, J = 10.3 Hz, 6.5 Hz, 1H, CH), 1.26 (h, J = 8.2 Hz, 7.6 Hz, 4H, CH2), 1.15–1.03 (m, 1H, CH). 13C NMR (101 MHz, DMSO-d6) δ 163.4, 160.5, 150.8, 149.9, 135.6, 131.4, 117.9, 98.7, 59.7, 49, 32.9, 25.6. LC-MS: 324.2 (M+H). Anal. Calculated for C18H21N5O: C, 64.57; H, 6.56; N, 19.82; found: C, 64.34; H, 6.44; N, 19.74%.
N-(4-Fluorobenzyl)-7-(4-methoxyphenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bb)
Yield = 86%; off-white solid. Mp 152–155 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H, NHCH2), 8.92 (t, J = 6.0 Hz, 1H, ArH), 7.58 (s, 1H, ArH), 7.32 (dd, J = 8.4, 5.6 Hz 2H, ArH), 7.15 (m, 4H, ArH), 6.98 (m, 2H, ArH), 6.18 (d, J = 3.8 Hz, 1H, NH), 5.65 (d, J = 4.1 Hz, 1H, CH), 4.41 (t, J = 5.6 Hz, 2H, CH2), 3.73 (s, 3H, OCH3). 13C NMR (100 MHz, DMSO-d6): δ 162.4, 150.2, 149.1, 133.7, 130.5, 129.4, 128.7, 115.5, 114.5, 101.9, 59, 55.6, 42.4. LC-MS: 380.1 (M+H). Anal. Calculated for C18H16F2N4: C, 63.32; H, 4.78; N, 18.46; found: C, 63.68; H, 5.06; N, 18.62%.
7-(4-Methoxyphenyl)-N-(1-phenylethyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bc)
Yield = 82%; off-white solid. Mp 162–165 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.59 (s, 1H, NHCH2), 8.72 (t, J = 7.4 Hz, 1H, ArH), 7.6 (s, 1H, ArH), 7.32 (d, J = 8.3 Hz 2H, ArH), 7.27–7.1 (m, 4H, ArH), 6.93 (t, J = 6.6 Hz 2H, ArH), 6.19 (d, J = 3.8 Hz, 1H, NH), 5.78 (d, J = 4.3 Hz, 1H, CH), 5.05 (p, J = 7.3 Hz, 1H, CH), 3.79 (s, 3H, OCH3), 1.49–1.33 (m, 3H, CH3). 13C NMR (100 MHz, DMSO-d6): δ 160.9, 159.6, 149.9, 149.1, 144.7, 133.7, 129.8, 128.7, 127.2, 126.5, 114.5, 102.3, 59.1, 55.6, 49.1, 22.3. LC-MS: 376.1 (M+H). Anal. Calculated for C18H16F2N4: C, 67.18; H, 5.64; N, 18.65; found: C, 67.07; H, 5.54; N, 18.45%.
N-Benzyl-7-(4-methoxyphenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6be)
Yield = 85%; off-white solid. Mp 157–160 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.7 (s, 1H, NHCH2), 8.94 (t, J = 6.0 Hz, 1H, ArH), 7.6 (s, 1H, ArH), 7.28 (m, 5H, ArH), 7.17 (d, J = 8.2 Hz, 2H, ArH), 6.92 (d, J = 8.2 Hz, 2H, ArH), 6.19 (d, J = 3.8 Hz, 1H, NH), 5.69 (d, J = 4.1 Hz, 1H, CH), 4.39 (t, J = 5.6 Hz, 2H, CH2), 3.73 (s, 3H, OCH3). 13C NMR (100 MHz, DMSO-d6): δ 161.9, 159.6, 150.2, 149.1, 139.4, 133.7, 130.1, 128.7, 127.9, 127.4, 114.5, 101.9, 59.1, 55.6, 43.1. LC-MS: 362.1 (M+H). Anal. Calculated for C18H16F2N4: C, 66.47; H, 5.30; N, 19.38; found: C, 66.68; H, 5.30; N, 19.36%.
7-(4-Methoxyphenyl)-N-(prop-2-yn-1-yl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bf)
Yield = 90%; off-white solid. Mp 141–144 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H, NHCH2), 8.84 (t, J = 5.6 Hz, 1H, ArH), 7.57 (s, 1H, ArH), 7.14 (d, J = 8.3 Hz, 2H, ArH), 6.9 (d, J = 8.3 Hz, 2H, ArH), 6.16 (d, J = 3.8 Hz, 1H, NH), 5.63 (d, J = 4.3 Hz, 1H, CH), 3.94 (dd, J = 5.67, 2.5 Hz, 2H, CH2), 3.71 (s, 3H, OCH3), 3.11 (t, J = 2.5 Hz, 1H, CH). 13C NMR (100 MHz, DMSO-d6): δ 167.7, 159.6, 150.2, 149.1, 133.7, 129.7, 128.7, 114.5, 102.3, 73.7, 58.9, 55.6. LC-MS: 310.1 (M+H). Anal. Calculated for C18H16F2N4: C, 62.13; H, 4.89; N, 22.64; found: C, 62.36; H, 4.59; N, 22.97%.
N-Ethyl-7-(4-methoxyphenyl)-N-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bg)
Yield = 76%; off-white solid. Mp 163–166 °C. 1H NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H, NH), 7.50–7.37 (m, 3H, ArH), 7.35–7.29 (m, 2H, ArH), 6.78–6.69 (m, 2H, ArH), 6.60 (d, J = 8.2 Hz, 2H, ArH), 6.25 (d, J = 3.5 Hz, 1H, ArH), 4.61 (d, J = 3.5 Hz, 1H), 3.93 (m, 1H, CH), 3.73 (s, 3H, OCH3), 3.64 (m, 1H, CH), 1.08 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, DMSO-d6): δ 163.9, 159.9, 149.5, 142.4, 131.9 130.1, 129.2, 127.9, 114.4, 100.5, 58.1, 55.7, 44.6, 12.9. LC-MS: 375.1 (M+H). Anal. Calculated for C19H23N5O2: C, 67.18; H, 5.64; N, 18.65; found: C, 66.98; H, 5.60; N, 18.85%.
N-(4-Chlorophenyl)-7-(4-methoxyphenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bh)
Yield = 81%; off-white solid. Mp 152–155 °C. 1H NMR (401 MHz, DMSO-d6) δ 10.42 (s, 1H, NH), 7.66–7.71 (m, 1H, ArH), 7.44–7.4 (m, 1H, 4H), 7.33 (m, 2H, ArH), 7.01 (m, 2H, ArH), 6.33 (dd, J = 9.1, 3.1 Hz, 1H), 5.93 (t, J = 3.5 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) 6 160.91, 160.43, 150.85, 149.81, 135.62 (d, J = 8.1 Hz), 131.62, 129.02, 128.24, 122.53, 100.47, 60.01 (d, J = 41.3 Hz). LC-MS: 382.1 (M+H). Anal. Calculated for C19H16ClN5O2: C, 59.77; H, 4.22; N, 18.34; found: C, 59.62; H, 4.53; N, 18.52%.
N-Cyclohexyl-7-(4-methoxyphenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6bi)
Yield = 80%; off-white solid. Mp 162–165 °C. 1H NMR (400 MHz, DMSO-d6): δ 10.15 (s, 1H, NH), 8.21 (d, J = 7.8 Hz, 1H, ArH), 7.29–719 (m, 2H, ArH), 7.03–6.92 (m, 2H, ArH), 6.55 (d, J = 3.6 Hz, 1H, ArH), 5.74 (d, J = 3.7 Hz, 1H, CH), 3.76 (s, 3H, OCH3), 3.66 (m, 1H, CH), 1.84–1.65 (m, 4H, CH2), 1.58 (dd, J = 10.3 Hz, 6.5 Hz, 1H, CH), 1.26 (h, J = 8.2 Hz, 7.6 Hz, 4H, CH2), 1.15–1.03 (m, 1H, CH). 13C NMR (100 MHz, DMSO-d6): δ 160.4, 160, 150.6, 132.6, 130.2, 129, 114.8, 101.8, 58.4, 55.7, 49, 32.6, 25 LC-MS: 354.4 (M+H). Anal. Calculated for C19H23N5O2: C, 64.57; H, 6.56; N, 19.82; found: C, 64.34; H, 6.44; N, 19.74%.
7-(5-Bromo-2-fluorophenyl)-N-(4-fluorobenzyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6cb)
Yield = 80%; off-white solid. Mp 176–178 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H, NHCH2), 8.97 (t, J = 5.9 Hz, 1H, ArH), 7.77–7.63 (m, 2H, ArH), 7.32 (dd, J = 8.4, 5.5 Hz, 2H, ArH), 7.23–7.08 (m, 3H, ArH), 6.86–6.74 (m, 1H, ArH), 6.53 (d, J = 3.6 Hz, 1H, ArH), 5.63 (d, J = 3.6 Hz, 1H, NH), 4.43–4.27 (t, J = 4.8 Hz, 2H, CH2). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 162.9, 161.6, 160.8, 160.5, 150.7, 149.9, 141.7, 135.5, 131.3, 129.9, 117.9, 116.6, 115.8, 115.4, 98.8, 59.7, 42.4. LC-MS: 446.1 (M+H). Anal. Calculated for C18H16F2N4: C, 51.14; H, 3.16; N, 15.69; found: C, 51.28; H, 2.99; N, 15.31%.
7-(5-Bromo-2-fluorophenyl)-N-(1-phenylethyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5-carboxamide (6cc)
Yield = 78%; off-white solid. Mp 172–174 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H, NHCH2), 8.74 (t, J = 7.1 Hz, 1H, ArH), 7.72 (m, 1H, ArH), 7.68 (d, J = 2.3 Hz, 2H, ArH), 7.32 (dd, J = 6.6, 4.4 Hz, 5H, ArH), 7.20 (m, 2H, ArH), 6.89–6.77 (m, 1H, ArH), 6.53 (d, J = 3.6 Hz, 1H, ArH),1.42 (dd, J = 7.0, 4.7 Hz, 3H, CH3). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 160.9, 160.7, 150.7, 149.8, 144.6, 141.8, 135.6, 131.3, 128.7, 127.2, 126.5, 117.9, 116.7, 115.9, 98.9, 49.1, 22.3. LC-MS: 442.1 (M+H). Anal. Calculated for C18H16F2N4: C, 54.31; H, 3.87; N, 15.83; found: C, 54.49; H, 3.50; N, 16.03%.
N-Benzyl-7-(5-bromo-2-fluorophenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ce)
Yield = 83%; off-white solid. Mp 171–174 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H, NHCH2), 8.98 (t, J = 5.9 Hz, 1H, ArH), 7.74–7.61 (m, 2H, ArH), 7.34–7.12 (m, 6H, ArH), 6.79 (dd, J = 9.3, 3.1 Hz, 1H, ArH), 6.52 (d, J = 3.6 Hz, 1H, ArH), 5.64 (d, J = 3.6 Hz, 1H, NH), 4.43–4.27 (t, J = 4.8 Hz, 2H, CH2). 13C NMR (100 MHz, DMSO-d6): δ 163.3, 161.5, 160.9, 150.8, 149.9, 141.8, 139.3, 135.6, 131.3, 129.1, 128.7, 127.9, 127.3, 118, 117.8, 116.8, 116.5, 115.8, 59.7, 43.1. LC-MS: 428.1 (M+H). Anal. Calculated for C18H16F2N4: C, 53.29; H, 3.53; N, 16.35; found: C, 53.22; H, 3.75; N, 16.60%.
7-(5-Bromo-2-fluorophenyl)-N-(prop-2-yn-1-yl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6cf)
Yield = 75%; off-white solid. Mp 162–164 °C. 1H NMR (400 MHz, DMSO-d6): δ 9.88 (s, 1H, NHCH2), 8.88 (t, J = 5.6 Hz, 1H, ArH), 7.73 (m, 1H, ArH), 7.68 (s, 1H, ArH), 7.21 (m, 1H, ArH), 6.79 (d, J = 4.3 Hz, 1H, CH), 6.51 (d, J = 3.8 Hz, 1H, NH), 5.61 (d, J = 4.3 Hz, 1H, CH), 3.94 (dd, J = 5.67, 2.5 Hz, 2H, CH2). 13C NMR (100 MHz, DMSO-d6): δ 167.7, 159.6, 150.2, 149.1, 133.7, 129.7, 128.7, 114.5, 102.3, 58.9, 55.6. LC-MS: 376.1 (M+H). Anal. Calculated for C18H16F2N4: C, 47.89; H, 2.95; N, 18.62; found: C, 47.79; H, 2.66; N, 18.25%.
7-(5-Bromo-2-fluorophenyl)-N-ethyl-N-phenyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6cg)
Yield = 77%; off-white solid. Mp 177–181 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H, NH), 7.67 -7.52 (m, 2H, ArH), 7.28–7.18 (m, 4H, ArH), 7.18–7.1 (me, ZF), 6,2 (dd, J = 3.7, 1.3 Hz, 1H, ArH), 5.87 (s, 1H, CH), 4.61 (d, J = 3.5 Hz, 1H, CH), 3.86 (m, 1H, CH2CH3), 3.63 (m, 1H, CH2CH3), 1.05 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, DMSO-d6): δ 163.8, 150.7, 149.3, 142.2, 135.1, 132.4, 129.5, 127.6, 117.7, 98.1, 58.9, 44.4, 12.9. LC-MS: 443.1 (M+2H). Anal. Calculated for C18H19BrFN5O: C, 51.44; H, 4.56; N, 16.66; found: C, 51.23; H, 4.68; N, 16.77%.
7-(5-Bromo-2-fluorophenyl)-N-(4-chlorophenyl)-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ch)
Yield = 74%; yellow solid. Mp 144–147 °C. 1H NMR (401 MHz, DMSO-d6) δ 10.53 (dd, J = 8.1, 3.2 Hz, 1H,), 10.16 (s, 1H, NH), 7.83–7.67 (m, 4H, ArH), 7.44–7.36 (m, 2H, ArH), 7.22 (m, 1H, ArH), 6.91 (dd, J = 9.1, 3.1 Hz, 1H), 6.60 (d, J = 3.7 Hz, 1H), 5.90 (t, J = 3.5 Hz, 1H). 13C NMR (101 MHz, DMSO-d6): δ 160.9, 160.4, 150.8, 149.8, 135.6, 131.6, 129.1, 128.2, 122.5, 100.5, 60.1. LC-MS: 449.1 (M+2H). Anal. Calculated for C18H19BrFN5O: C, 48.18; H, 2.70; N, 15.61; found: C, 48.13; H, 2.92; N, 15.72%.
7-(5-Bromo-2-fluorophenyl)-N-cyclohexyl-3,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxamide (6ci)
Yield = 78%; off-white solid. Mp 173–177 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H, NH), 8.15 (d, J = 7.7 Hz, 1H, ArH), 7.73 (dd, J = 8.8, 53.2 Hz, 1H, ArH), 7.69 (s, 1H, ArH), 7.20 (m, 1H, ArH), 6.80 (dd, J = 9.4, 3.1 Hz, 1H, ArH), 6.52 (d, J = 3.7 Hz, 1H, ArH), 5.62 (d, J = 3.7 Hz, 1H, CH), 3.65 (m, 1H, CH2), 1.85–1.66 (m, 4H, CH2), 1.66–1.52 (m, 1H, CH), 1.34–1.17 (m, 4H, CH2), 1.47–1.01 (m, 1H, CH). 13C NMR (101 MHz, DMSO-d6): δ 163.4, 160.5, 150.8, 149.9, 141.9, 135.6, 131.4, 117.9, 116.7, 115.9, 98.7, 59.7, 49, 32.9, 25.6, 25.3. LC-MS: 421.1 (M+2H). Anal. Calculated for C18H19BrFN5O: C, 51.44; H, 4.56; N, 16.66; found: C, 51.23; H, 4.68; N, 16.77%.

3.2.3. General Procedure for the Gram-Scale Reaction

Sulfuryl chloride (20 mmol, 2.0 equiv.) was added to a solution of N-methyl imidazole (20 mmol, 2.0 equiv.) in dichloromethane (10 vol) and stirred for 15 min. To that mixture, benzoic acid 4d (10 mmol, 1.0 equiv.) was added, followed by benzyl amine 5e (1.2 equiv.). The reaction mixture was stirred for 5 h at room temperature and then quenched with water (10 vol). The organic layer was washed with saturated sodium bicarbonate solution (10 mL) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under a vacuum. The residue obtained was washed with dichloromethane to obtain the desired N-benzyl-benzamide as a white solid in a 75% yield. The melting point and spectral characteristics were found to match with the reported values [35].

3.2.4. Procedure for Determining In Vitro Anti-Inflammatory Activity: Anti-Denaturation Assay

The experiment was performed according to a previously reported protocol [36]. The extracts of the target compounds or drugs were dissolved in a minimum quantity of DMSO and diluted with phosphate buffer (0.2 M, PH 7.4). It was carefully noted that the final concentration of DMSO in all the solutions was less than 2.5%. The test solution (4 mL) containing various concentrations of the target compounds was mixed with 1 mL of 1 mM solution of albumin in phosphate buffer and incubated for 15 min at 37 °C. Denaturation was induced by placing the reaction mixture in a water bath at 70 °C for 15 min. The reaction mixture was cooled after 15 min, and the turbidity was measured at 660 nm. A control experiment was also carried out without adding the tested target compounds. Diclofenac sodium was employed as the standard drug for reference purposes. The percentage of the inhibition of denaturation was calculated from the control by using the following formula:
% of Inhibition = 100 × (At − Ac)/At
where At = optical density of the test solution; Ac = optical density of the control.

3.2.5. Procedure for Determining Anti-Tubercular Potential

The in vitro antimycobacterial activity of the target compounds were determined by the resazurin assay method. The compounds were examined against M. tuberculosis H37Rv American Type Culture Collection (ATCC) 27294 and non-tubercular mycobacterial (NTM) species such as the M. smegmatis (MC2) ATCC 19420, M. fortuitum ATCC 19542 and MDR-TB strains. The MIC values for each target compound were determined against the tested tubercular strains. The standard drugs used for reference were isoniazid and rifampicin. The M. tuberculosis strains were full-grown in Middlebrook 7H9 broth (Difco BBL, Sparks, MD, USA) and supplemented by 10% oleic albumin dextrose catalase (OADC, Becton Dickinson, Sparks, MD, USA). Using the same medium, the culture was then diluted to McFarland 2 standard. A total of 50 mL of the culture from this standard solution was then added to 150 mL of fresh medium in 96 well microtiter plates. The test compounds were prepared as stock solutions (2 mg/mL) in N,N-Dimethyl formamide (DMF). Initially, the target compounds were tested at 1, 10 and 100 μg/mL concentrations. Later, the second level of testing was carried out for the more active compounds at 0.3125, 0.625, 1.25, 2.5 and 5 μg/mL concentrations. The control tubes were made up to the same volumes of DMF without any substrate. After incubating the stock solution at 37 °C for 7 days, each tube had 20 mL of 0.01% resazurin in water (Sigma, St. Louis, MO, USA) added to it. Resazurin is a redox dye that is blue in the oxidized state and turns pink when reduced by the growth of viable cells. The control tubes showed a change of color from blue to pink after 1 h at 37 °C. The test compounds that prevented the color change of the dye were considered to be inhibitory against the tested TB strains. Each experiment was carried out in triplicate.

4. Conclusions

We have successfully synthesized a series of novel dihydrotriazolopyrimidine amides by utilizing NMI-SO2Cl2-mediated amide bond formation reactions. The developed protocol can be employed as an alternative methodology to access challenging heterocyclic amide bonds with multiple hetero atoms. As evident from the success of our gram-scale reaction between benzoic acid and benzyl amine, this protocol could be applied to the coupling reaction of simple molecules. All the newly synthesized molecules were screened for their in vitro anti-inflammatory and anti-tubercular potential, and from those studies, it was found that some of the compounds exhibited promising activity profiles when compared with their respective reference standards. The SAR studies underlined the importance of the presence of electron-donating substituents in improving the anti-inflammatory potential. However, the presence of electron-withdrawing functionalities was found to be necessary for enhancing the anti-tubercular activity of the synthesized compounds.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph17050548/s1, the NMR spectra of all the new compounds tested in this study.

Author Contributions

Conceptualization, methodology: A.B., K.S. and A.M.S.; formal analysis: E.K.R., S.S. and G.V.Z.; investigation: S.B. and M.N.J.; draft preparation and editing: S.B., T.V. and M.N.J.; supervision: K.S. and M.N.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement # 075-15-2022-1118 from 29 June 2022). Sougata Santra is thankful to the Russian Science Foundation (Grant # 24-23-00516).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Acknowledgments

Aravinda Babu is thankful to Syngene International Ltd. for providing the No Objection Certificate (NOC) regarding his doctoral work. The authors are thankful to the Sri Siddhartha Academy of Higher Education and Karnataka Council for Technological Upgradation (KCTU) for providing all the facilities to carry out this research work.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Romdhane, A.; Said, A.B.; Cherif, M.; Jannet, H.B. Design, synthesis and anti-acetylcholinesterase evaluation of some new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives. Med. Chem. Res. 2016, 25, 1358–1368. [Google Scholar] [CrossRef]
  2. Singh, P.K.; Silakari, O. Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET. Bioorg. Chem. 2018, 79, 163–170. [Google Scholar] [CrossRef] [PubMed]
  3. Singh, P.K.; Silakari, O. In silico guided development of imine-based inhibitors for resistance-deriving kinases. J. Biomol. Struct. Dyn. 2019, 37, 2593–2599. [Google Scholar] [CrossRef] [PubMed]
  4. Bakulev, V.A.; Shafran, Y.M.; Beliaev, N.A.; Beryozkina, T.V.; Volkova, N.N.; Joy, M.N.; Fan, Z. Heterocyclic azides: Advances in their chemistry. Russ. Chem. Rev. 2022, 91, RCR5042. [Google Scholar] [CrossRef]
  5. Singh, P.K.; Choudhary, S.; Kashyap, A.; Verma, H.; Kapil, S.; Kumar, M.; Arora, M.; Silakari, O. An exhaustive compilation on chemistry of triazolopyrimidine: A journey through decades. Bioorg. Chem. 2019, 88, 102919. [Google Scholar] [CrossRef] [PubMed]
  6. El-Sayed, W.A.; Ali, O.M.; Faheem, M.S.; Zied, I.F.; Abdel-Rahman, A.A.H. Synthesis and antimicrobial activity of new 1,2,3-triazolopyrimidine derivatives and their glycoside and acyclic nucleoside analogs. J. Heterocycl. Chem. 2012, 49, 607–612. [Google Scholar] [CrossRef]
  7. Nettekoven, M.; Adam, J.M.; Bendels, S.; Bissantz, C.; Fingerle, J.; Grether, U.; Grüner, S.; Guba, W.; Kimbara, A.; Ottaviani, G.; et al. Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases. ChemMedChem 2016, 11, 179–189. [Google Scholar] [CrossRef] [PubMed]
  8. Coteron, J.M.; Marco, M.; Esquivias, J.; Deng, X.; White, K.L.; White, J.; Koltun, M.; Mazouni, F.E.; Kokkonda, S.; Katneni, K.; et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem. 2011, 54, 5540–5561. [Google Scholar] [CrossRef] [PubMed]
  9. Hassan, G.S.; El-Sherbeny, M.A.; El-Ashmawy, M.B.; Bayomi, S.M.; Maarouf, A.R.; Badria, F.A. Synthesis and antitumor testing of certain new fused triazolopyrimidine and triazoloquinazoline derivatives. Arab. J. Chem. 2017, 10, S1345–S1355. [Google Scholar] [CrossRef]
  10. Omar, A.M.; Razik, H.A.A.E.; Hazzaa, A.A.; El-Attar, M.A.; Demellawy, M.A.E.; Wahab, A.E.A.; Hawash, S.A.M.E. New pyrimidines and triazolopyrimidines as antiproliferative and antioxidants with cyclooxygenase-1/2 inhibitory potential. Future Med. Chem. 2019, 11, 1583–1603. [Google Scholar] [CrossRef]
  11. Kumar, J.; Meena, P.; Singh, A.; Jameel, E.; Maqbool, M.; Mobashir, M.; Shandilya, A.; Tiwari, M.; Hoda, N.; Jayaram, B. Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer′s disease therapies. Eur. J. Med. Chem. 2016, 119, 260–277. [Google Scholar] [CrossRef]
  12. Kumar, J.; Gill, A.; Shaikh, M.; Singh, A.; Shandilya, A.; Jameel, E.; Sharma, N.; Mrinal, N.; Hoda, N.; Jayaram, B. Pyrimidine-triazolopyrimidine and pyrimidine-pyridine hybrids as potential acetylcholinesterase Inhibitors for Alzheimer′s disease. Chemistryselect 2018, 3, 736–747. [Google Scholar] [CrossRef]
  13. Jameel, E.; Meena, P.; Maqbool, M.; Kumar, J.; Ahmed, W.; Mumtazuddin, S.; Tiwari, M.; Hoda, N.; Jayaram, B. Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents. Eur. J. Med. Chem. 2017, 136, 36–51. [Google Scholar] [CrossRef] [PubMed]
  14. Rishikesan, R.; Karuvalam, R.P.; Joy, M.N.; Sajith, A.M.; Reddy, E.K.; Pakkath, R.; Haridas, K.R.; Bhaskar, V.; Narasimhamurthy, K.H.; Muralidharan, A. Synthesis of some novel piperidine fused 5-thioxo-1H-1,2,4-triazoles as potential antimicrobial and antitubercular agents. J. Chem. Sci. 2017, 133, 3. [Google Scholar] [CrossRef]
  15. Gupta, O.; Pradhan, T.; Chawla, G. An updated review on diverse range of biological activities of 1,2,4-triazole derivatives: Insight into structure activity relationship. J. Mol. Struct. 2023, 1274, 134487. [Google Scholar] [CrossRef]
  16. Aggarwal, R.; Sumran, G. An insight on medicinal attributes of 1,2,4-triazoles. Eur. J. Med. Chem. 2020, 205, 112652. [Google Scholar] [CrossRef]
  17. Koksal, M.; Ozkan-Dagliyan, I.; Ozyazici, T.; Kadioglu, B.; Sipahi, H.; Bozkurt, A.; Bilge, S.S. Some novel Mannich bases of 5-(3,4-dichlorophenyl)-1,3,4-oxadiazole-2(3H)-one and their anti-inflammatory activity. Arch. Pharm. 2017, 350, e1700153. [Google Scholar] [CrossRef]
  18. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50, 1425–1441. [Google Scholar] [CrossRef] [PubMed]
  19. Khan, K.M.; Ambreen, N.; Mughal, U.R.; Jalil, S.; Perveen, S.; Choudhary, M.I. 3-Formylchromones: Potential antiinflammatory agents. Eur. J. Med. Chem. 2010, 45, 4058–4064. [Google Scholar] [CrossRef]
  20. Feng, Y.; Guo, M.; Jia, X.; Liu, N.; Li, X.; Li, X.; Song, L.; Wang, X.; Qiu, L.; Yu, Y. Combined effects of electrical current and nonsteroidal antiinflammatory drugs (NSAIDs) on microbial community in a three-dimensional electrode biological aerated filter (3DE-BAF). Bioresour. Technol. 2020, 309, 123346. [Google Scholar] [CrossRef]
  21. Glomb, T.; Wiatrak, B.; Gebczak, K.; Gebarowski, T.; Bodetko, D.; Czyznikowska, Z.; Swiatek, P. New 1,3,4-oxadiazole derivatives of pyridothiazine-1,1-dioxide with anti-inflammatory activity. Int. J. Mol. Sci. 2020, 21, 9122. [Google Scholar] [CrossRef] [PubMed]
  22. Matteo, Z.; Anna, S.D.; Dennis, F.; Wayne van, G.; Abigail, W.; Armand van, D.; Françoise, P.; Adalbert, L.; Marcos, A.E.; Ariel, P.M.; et al. Twenty years of global surveillance of antituberculosis-drug resistance. N. Engl. J. Med. 2016, 375, 1081–1089. [Google Scholar]
  23. Global Tuberculosis Report 2022; World Health Organization: Geneva, Switzerland, 2022.
  24. Norton, P.P. Drug resistance: A growing problem. Drug Discov. Today 2010, 15, 583–586. [Google Scholar]
  25. Sanna, P.; Carta, A.; Nikookar, M.E. Synthesis and antitubercular activity of 3-aryl substituted-2-(1H(2H)benzotriazol-1(2)-yl)acrylonitriles. Eur. J. Med. Chem. 2000, 35, 535–543. [Google Scholar] [CrossRef] [PubMed]
  26. Joy, M.N.; Bakulev, V.A.; Bodke, Y.D.; Telkar, S. Synthesis of coumarins coupled with benzamides as potent antimicrobial agents. Pharm. Chem. J. 2020, 54, 604–621. [Google Scholar] [CrossRef]
  27. Joy, M.N.; Guda, M.R.; Zyryanov, G.V. Evaluation of anti-inflammatory and anti-tubercular activity of 4-methyl-7-substituted coumarin hybrids and their structure activity relationships. Pharmaceuticals 2023, 16, 1326. [Google Scholar] [CrossRef] [PubMed]
  28. Rajendra, M.A.; Naseem, M.; Joy, M.N.; Sunil, K.; Sajith, A.M.; Howari, F.; Nazzal, Y.; Xavier, C.; Alshammari, M.B.; Haridas, K.R. Application of NMI-TfCl mediated amide bond formation in the synthesis of biologically relevant oxadiazole derivatives employing less basic (hetero)aryl amines. Mol. Divers. 2022, 26, 1761–1767. [Google Scholar] [CrossRef] [PubMed]
  29. Joy, M.N.; Bodke, Y.D.; Telkar, S.; Bakulev, V.A. Synthesis of coumarins linked with 1,2,3-triazoles under microwave irradiation and evaluation of their antimicrobial and antioxidant activity. J. Mex. Chem. Soc. 2020, 64, 53–73. [Google Scholar]
  30. Reddy, E.K.; Remya, C.; Sajith, A.M.; Dileep, K.V.; Sadasivan, C.; Anwar, S. Functionalised dihydroazo pyrimidine derivatives from Morita–Baylis–Hillman acetates: Synthesis and studies against acetylcholinesterase as its inhibitors. RSC Adv. 2016, 6, 77431–77439. [Google Scholar] [CrossRef]
  31. Priya, M.G.R.; Girija, K.; Ravichandran, N. Invitro study of anti-inflammatory and antioxidant activity of 4-(3H)-quinazolinone derivatives. Rasayan J. Chem. 2011, 4, 418–424. [Google Scholar]
  32. Neetu, K.T.; Jaya, S.T. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother. 2007, 60, 288–293. [Google Scholar]
  33. Parker, M.A.; Kurrasch, D.M.; Nichols, D.E. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem. 2008, 16, 4661–4669. [Google Scholar] [CrossRef] [PubMed]
  34. Fulmer, G.R.; Miller, A.J.M.; Sherden, N.H.; Gottlieb, H.E.; Nudelman, A.; Stoltz, B.M.; Bercaw, J.E.; Goldberg, K.I. NMR chemical shifts of trace impurities: Common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist. Organometallics 2010, 29, 2176–2179. [Google Scholar] [CrossRef]
  35. Metro, T.S.; Bonnamour, J.; Reidon, T.; Duprez, A.; Sarpoulet, J.; Martinez, J.; Lamaty, F. Comprehensive study of the organic-solvent-free CDI-mediated acylation of various nucleophiles by mechanochemistry. Chem. Eur. J. 2015, 21, 12787–12796. [Google Scholar] [CrossRef]
  36. Kulkarni, B.; Manjunatha, K.; Joy, M.N.; Sajith, A.M.; Prashantha, C.N.; Pakkath, R.; Alshammari, M.B. Design, synthesis and molecular docking studies of some 1-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-3-yl)piperazine derivatives as potential anti-inflammatory agents. Mol. Divers. 2022, 26, 2893–2905. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00548 sch001
Scheme 1. Synthesis of key acid intermediates 4a–c.
Scheme 1. Synthesis of key acid intermediates 4a–c.
Pharmaceuticals 17 00548 sch001
Pharmaceuticals 17 00548 sch002
Scheme 2. Synthesis of the final compounds; the isolated yield is given in parentheses.
Scheme 2. Synthesis of the final compounds; the isolated yield is given in parentheses.
Pharmaceuticals 17 00548 sch002
Pharmaceuticals 17 00548 sch003
Scheme 3. Gram-scale reaction of benzoic acid with benzyl amine.
Scheme 3. Gram-scale reaction of benzoic acid with benzyl amine.
Pharmaceuticals 17 00548 sch003
Pharmaceuticals 17 00548 sch004
Scheme 4. Proposed mechanism for the formation of the key acid intermediates 4a–c.
Scheme 4. Proposed mechanism for the formation of the key acid intermediates 4a–c.
Pharmaceuticals 17 00548 sch004
Pharmaceuticals 17 00548 sch005
Scheme 5. Proposed mechanism for the formation of the final products 6.
Scheme 5. Proposed mechanism for the formation of the final products 6.
Pharmaceuticals 17 00548 sch005
Pharmaceuticals 17 00548 sch006
Scheme 6. SAR studies of the newly synthesized compounds 6aa–6ci.
Scheme 6. SAR studies of the newly synthesized compounds 6aa–6ci.
Pharmaceuticals 17 00548 sch006
Table 1. Optimization of the reaction conditions a.
Table 1. Optimization of the reaction conditions a.
Pharmaceuticals 17 00548 i001
EntryAcid
(Equiv.)		Amine
(Equiv.)		NMI
(Equiv.)		SO2Cl2
(Equiv.)		Yield b
6aa (%)
1112280
2 c11.22292
31.212280
411.21175
Deviation from the above standard conditions (entry 2)
5EDC HCl and HOBT instead of NMI-SO2Cl265
6DIPEA and HATU instead of NMI- SO2Cl270
7TEA instead of NMI40
8T3P instead of SO2Cl250
9TCFH instead of SO2Cl275
10TfCl instead of SO2Cl282
11MsCl instead of SO2Cl280
12DMF instead of DCM70
13THF instead of DCM60
a Reaction conditions: acid 4a (1.0 mmol), amine 5a (1.2 mmol), NMI (2.0 mmol), SO2Cl2 (2.0 mmol), solvent (3 mL), RT, 2 h. b Isolated yield. c Optimized reaction condition in bold.
Table 2. In vitro anti-inflammatory activity studies of compounds 6aa–6ci a.
Table 2. In vitro anti-inflammatory activity studies of compounds 6aa–6ci a.
Compounds% Inhibition of Denaturation at Different Concentrations
100 μg/mL200 μg/mL400 μg/mL800 μg/mL1600 μg/mL
6aa40 ± 0.6552 ± 0.7962 ± 1.4574 ± 0.5988 ± 0.38
6ab20 ± 0.1932 ± 0.2345 ± 0.3658 ± 0.8570 ± 1.14
6ac37 ± 0.4949 ± 0.5460 ± 1.1076 ± 1.0484 ± 0.85
6ad22 ± 0.4933 ± 1.2344 ± 0.4760 ± 0.6772 ± 0.84
6af25 ± 0.2738 ± 0.2849 ± 1.0162 ± 0.0875 ± 0.66
6ag18 ± 0.2129 ± 0.6840 ± 0.3552 ± 0.5865 ± 0.93
6ai8 ± 0.4520 ± 0.4533 ± 1.1246 ± 0.1657 ± 0.17
6bb21 ± 0.4732 ± 0.5444 ± 0.4459 ± 0.5572 ± 1.06
6bc35 ± 1.2248 ± 1.0660 ± 1.0471 ± 0.6382 ± 1.08
6be44 ± 0.4955 ± 0.1867 ± 0.7680 ± 0.3494 ± 0.48
6bf24 ± 1.2239 ± 0.7550 ± 0.8561 ± 1.1270 ± 1.42
6bg36 ± 0.7647 ± 1.1259 ± 0.4570 ± 0.2684 ± 1.14
6bh23 ± 0.7432 ± 0.5840 ± 0.7753 ± 1.0269 ± 0.92
6bi17 ± 0.1827 ± 0.8539 ± 0.6450 ± 1.1561 ± 1.36
6cb8 ± 0.4619 ± 0.1830 ± 0.0543 ± 1.0355 ± 0.05
6cc6 ± 1.0517 ± 1.1626 ± 0.6538 ± 0.1250 ± 0.45
6ce10 ± 1.1125 ± 1.1235 ± 0.1447 ± 0.0459 ± 0.12
6cf11 ± 1.0523 ± 0.1736 ± 0.6548 ± 0.0256 ± 1.01
6cg20 ± 0.6733 ± 0.6945 ± 0.8858 ± 0.4770 ± 0.30
6ch14 ± 0.1424 ± 0.4436 ± 1.0950 ± 0.5163± 0.14
6ci12 ± 0.5625 ± 0.1538 ± 1.5451 ± 1.1460 ± 0.17
Diclofenac41 ± 0.1657 ± 0.4880 ± 0.8486 ± 1.0289 ± 1.06
a The experiments were performed in triplicate and expressed as the mean ± SD.
Table 3. Anti-tubercular activity data of the synthesized compounds 6aa–6ci.
Table 3. Anti-tubercular activity data of the synthesized compounds 6aa–6ci.
Preliminary In Vitro Screening Results, MIC (μg/mL)Second-Level Screening Results, MIC (μg/mL)
CompoundMTB aMS bMF c% dMTBMSMFMDR-TB
6aa>100>100>1000----
6ab1 ± 0.2010 ± 0.1410 ± 0.35901.25 ± 0.382.5 ± 0.16>512.5 ± 0.28
6ac>100>100>1000----
6ad10 ± 0.1410 ± 0.23>100<90>5>5>5>50
6af10 ± 0.2810 ± 0.2210 ± 0.12<90>5>5>5>50
6ag>100>100>1000----
6ai>100>100>1000----
6bb10 ± 0.4510 ± 0.80>100<90>5->5>50
6bc>100>100>1000----
6be>100>100>1000----
6bf>100>100>1000----
6bg>100>100>1000----
6bh10 ± 0.3210 ± 0.0410 ± 0.2810± 0.3010 ± 0.4510 ± 0.3610 ± 0.2010 ± 0.55
6bi>100>100>1000----
6cb1 ± 0.181 ± 0.2910 ± 0.45950.625 ± 0.111.25 ± 0.205 ± 0.376.25 ± 0.18
6cc1 ± 0.4010 ± 0.141 ± 0.35901.25 ± 0.461.25 ± 0.20>512.5 ± 0.28
6ce1 ± 0.401 ± 0.3610 ± 0.5590>51.25 ± 0.20>525 ± 0.26
6cf1 ± 0.3810 ± 0.141 ± 0.35901.25 ± 0.141.25 ± 0.40>512.5 ± 0.62
6cg1 ± 0.2010 ± 0.311 ± 0.44901.25 ± 0.241.25 ± 0.25>512.5 ± 0.29
6ch1 ± 0.151 ± 0.2510 ± 0.35950.625 ± 0.071.25 ± 0.115 ± 0.276.25 ± 0.07
6ci1 ± 0.391 ± 0.2410 ± 0.3990>51.25 ± 0.31>525 ± 0.42
Isoniazid0.7 ± 0.0550 ± 0.2512.5 ± 0.34950.7 ± 0.0850 ± 0.2112.5 ± 0.1812.5 ± 0.20
Rifampicin0.5 ± 0.351.5 ± 0.381.5 ± 0.34950.5 ± 0.411.5 ± 0.161.5 ± 0.2225 ± 0.21
a Mycobacterium tuberculosis H37Rv; b Mycobacterium smegmatis (ATCC 19420); c Mycobacterium fortuitum (ATCC 19542); d percentage of inhibition against M. tuberculosis H37Rv; ‘-’ not detected. The MIC values were determined in triplicate and expressed as the mean ± SD.
Table 4. Calculated LogP and CLogP values for the synthesized compounds 6aa–6ci.
Table 4. Calculated LogP and CLogP values for the synthesized compounds 6aa–6ci.
CompoundsLogPCLogP
6aa2.301.7159
6ab2.581.9399
6ac2.742.1059
6ad0.690.9292
6af0.910.6929
6ag2.933.1377
6ai2.242.1239
6bb2.451.9840
6bc2.612.1500
6be2.301.8410
6bf0.780.7370
6bg2.803.0567
6bh2.782.7994
6bi2.112.1680
6cb3.572.9459
6cc3.733.1119
6ce3.412.9280
6cf1.891.8240
6cg3.914.1437
6ch3.903.8864
6ci3.223.2550
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Babu, A.; Sunil, K.; Sajith, A.M.; Reddy, E.K.; Santra, S.; Zyryanov, G.V.; Venkatesh, T.; Bhadrachari, S.; Nibin Joy, M. NMI-SO2Cl2-Mediated Amide Bond Formation: Facile Synthesis of Some Dihydrotriazolopyrimidine Amide Derivatives as Potential Anti-Inflammatory and Anti-Tubercular Agents. Pharmaceuticals 2024, 17, 548. https://doi.org/10.3390/ph17050548

AMA Style

Babu A, Sunil K, Sajith AM, Reddy EK, Santra S, Zyryanov GV, Venkatesh T, Bhadrachari S, Nibin Joy M. NMI-SO2Cl2-Mediated Amide Bond Formation: Facile Synthesis of Some Dihydrotriazolopyrimidine Amide Derivatives as Potential Anti-Inflammatory and Anti-Tubercular Agents. Pharmaceuticals. 2024; 17(5):548. https://doi.org/10.3390/ph17050548

Chicago/Turabian Style

Babu, Aravinda, Kenchaiah Sunil, Ayyiliath Meleveetil Sajith, Eeda Koti Reddy, Sougata Santra, Grigory V. Zyryanov, Talavara Venkatesh, Somashekara Bhadrachari, and Muthipeedika Nibin Joy. 2024. "NMI-SO2Cl2-Mediated Amide Bond Formation: Facile Synthesis of Some Dihydrotriazolopyrimidine Amide Derivatives as Potential Anti-Inflammatory and Anti-Tubercular Agents" Pharmaceuticals 17, no. 5: 548. https://doi.org/10.3390/ph17050548

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop